Standardized pathology report for breast cancer

키워드

참고문헌 (55)

1. 강상율, "Breast Cancer Statistics in Korea in 2017: Data from a Breast Cancer Registry", Journal of Breast Cancer, 23(2), pp.115~128 (2020), 한국유방암학회[DOI]
2. Li X, "New developments in breast cancer and their impact on daily practice in pathology", Arch Pathol Lab Med, 141, pp.490~498 (2017)
3. "Protocol for the examination of resection specimens from patients with invasive carcinoma of the breast" (2020)[URL]
4. Hortobagyi GN, "AJCC cancer staging manual", pp.589~636 (2017), Springer
5. WHO Classification of Tumours Editorial Board, "WHO classification of tumours: breast tumours" (2019), International Agency for Research on Cancer
6. Lester SC, "Protocol for the examination of specimens from patients with invasive carcinoma of the breast", Arch Pathol Lab Med, 133, pp.1515~1538 (2009)
7. Salgado R, "Evolving paradigms in multifocal breast cancer", Semin Cancer Biol, 31, pp.111~118 (2015)
8. Andea AA, "Pathologic analysis of tumor size and lymph node status in multifocal", multicentric breast carcinoma, 2002, pp.94, 1383~1390
9. Weissenbacher TM, "Multicentric and multifocal versus unifocal breast cancer : is the tumor-node-metastasis classification justified?", Breast Cancer Res Treat, 122, pp.27~34 (2010)
10. Coombs NJ, "Multifocal and multicentric breast cancer : does each focus matter?", J Clin Oncol, 23, pp.7497~7502 (2005)
11. Choi Y, "The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal", multicentric invasive ductal carcinoma of breast, 2012, pp.43, 48~55
12. Elston CW, "Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up", Histopathology, 19, pp.403~410 (1991)
13. Rakha EA, "Prognostic significance of Nottingham histologic grade in invasive breast carcinoma", J Clin Oncol, 26, pp.3153~3158 (2008)
14. Jaffer S, "Histologic classification of ductal carcinoma in situ", Microsc Res Tech, 59, pp.92~101 (2002)
15. Grin A, "Measuring extent of ductal carcinoma in situ in breast excision specimens : a comparison of 4 methods", Arch Pathol Lab Med, 133, pp.31~37 (2009)
16. Morrow M, "Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ", Pract Radiat Oncol, 6, pp.287~295 (2016)
17. Choi AH, "Size of extranodal extension on sentinel lymph node dissection in the American College of Surgeons Oncology Group Z0011 trial era", JAMA Surg, 150, pp.1141~1148 (2015)
18. Mohammed RA, "Objective assessment of lymphatic and blood vascular invasion in lymph nodenegative breast carcinoma : findings from a large case series with long-term follow-up", J Pathol, 223, pp.358~365 (2011)
19. Provenzano E, "Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer : recommendations from an international working group", Mod Pathol, 28, pp.1185~1201 (2015)
20. Baker GM, "Evaluation of breast and axillary lymph node specimens in breast cancer patients treated with neoadjuvant systemic therapy", Adv Anat Pathol, 26, pp.221~234 (2019)
21. Hoda SA, "Rosen's breast pathology" (2014), Wolters Kluwer
22. Duraker N, "Perineural invasion has no prognostic value in patients with invasive breast carcinoma", Breast, 15, pp.629~634 (2006)
23. McCready DR, "Factors affecting distant disease-free survival for primary invasive breast cancer : use of a log-normal survival model", Ann Surg Oncol, 7, pp.416~426 (2000)
24. McCready DR, "Factors associated with local breast cancer recurrence after lumpectomy alone : postmenopausal patients", Ann Surg Oncol, 7, pp.562~567 (2000)
25. Owings DV, "How thoroughly should needle localization breast biopsies be sampled for microscopic examination? A prospective mammographic", pathologic correlative study, 1990, pp.14, 578~583
26. Silverstein MJ, "Image-detected breast cancer : state of the art diagnosis and treatment", J Am Coll Surg, 201, pp.586~597 (2005)
27. Aaltomaa S, "Lymphocyte infiltrates as a prognostic variable in female breast cancer", Eur J Cancer, 28, pp.859~864 (1992)
28. Wein L, "Clinical validity and utility of tumor-infiltrating lymphocytes in routine clinical practice for breast cancer patients : current and future directions", Front Oncol, 7, pp.156~ (2017)
29. Hendry S, "Assessing tumor-infiltrating lymphocytes in solid tumors : a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology Biomarkers Working Group : part 2 : TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors", Adv Anat Pathol, 24, pp.311~335 (2017)
30. Dieci MV, "Update on tumorinfiltrating lymphocytes(TILs)in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ : a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer", Semin Cancer Biol, 52, pp.16~25 (2018)
31. Denkert C, "Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer : results of the ring studies of the international immuno-oncology biomarker working group", Mod Pathol, 29, pp.1155~1164 (2016)
32. Kos Z, "Pitfalls in assessing stromal tumor infiltrating lymphocytes(sTILs)in breast cancer", NPJ Breast Cancer, 6, pp.17~ (2020)
33. Chevallier B, "Pilot study of intensive induction chemotherapy(FEC-HD)results in a high histologic response rate", Am J Clin Oncol, 16, pp.223~228 (1993)
34. Sataloff DM, "Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast : a determinant of outcome", J Am Coll Surg, 180, pp.297~306 (1995)
35. Fisher ER, "Pathobiology of preoperative chemotherapy : findings from the National Surgical Adjuvant Breast and Bowel(NSABP)protocol B-18", Cancer, 95, pp.681~695 (2002)
36. Ogston KN, "A new histological grading system to assess response of breast cancers to primary chemotherapy : prognostic significance and survival", Breast, 12, pp.320~327 (2003)
37. Symmans WF, "Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy", J Clin Oncol, 25, pp.4414~4422 (2007)
38. Mittendorf EA, "Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy", J Clin Oncol, 29, pp.1956~1962 (2011)
39. Chollet P, "A new prognostic classification after primary chemotherapy for breast cancer : residual disease in breast and nodes(RDBN)", Cancer J, 14, pp.128~132 (2008)
40. Mrkonjic M, "Breast specimen handling and reporting in the post-neoadjuvant setting : challenges and advances", J Clin Pathol, 72, pp.120~132 (2019)
41. Bossuyt V, "Processing and reporting of breast specimens in the neoadjuvant setting", Surg Pathol Clin, 11, pp.213~230 (2018)
42. Hennessy BT, "Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy", J Clin Oncol, 23, pp.9304~9311 (2005)
43. von Minckwitz G, "Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes", J Clin Oncol, 30, pp.1796~1804 (2012)
44. Pinder SE, "Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy", Histopathology, 50, pp.409~417 (2007)
45. Smith IC, "Neoadjuvant chemotherapy in breast cancer : significantly enhanced response with docetaxel", J Clin Oncol, 20, pp.1456~1466 (2002)
46. Allison KH, "Estrogen and progesterone receptor testing in breast cancer : ASCO", CAP guideline update, 2020, pp.38, 1346~1366
47. Wolff AC, "Human epidermal growth factor receptor 2 testing in breast cancer : American Society of Clinical Oncology", College of American Pathologists clinical practice guideline focused update, 2018, pp.36, 2105~2122
48. Harvey JM, "Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer", J Clin Oncol, 17, pp.1474~1481 (1999)
49. 안수민, "HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation", Journal of Pathology and Translational Medicine, 54(1), pp.34~44 (2020), 대한병리학회[DOI]
50. Wolff AC, "Recommendations for human epidermal growth factor receptor 2 testing in breast cancer : American Society of Clinical Oncology", College of American Pathologists clinical practice guideline update, 2013, pp.31, 3997~4013
51. Luporsi E, "Ki-67 : level of evidence and methodological considerations for its role in the clinical management of breast cancer : analytical and critical review", Breast Cancer Res Treat, 132, pp.895~915 (2012)
52. Yerushalmi R, "Ki67 in breast cancer : prognostic and predictive potential", Lancet Oncol, 11, pp.174~183 (2010)
53. Viale G, "Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer : results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole", J Clin Oncol, 26, pp.5569~5575 (2008)
54. Penault-Llorca F, "Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer", J Clin Oncol, 27, pp.2809~2815 (2009)
55. Dowsett M, "Assessment of Ki67 in breast cancer : recommendations from the International Ki67 in Breast Cancer working group", J Natl Cancer Inst, 103, pp.1656~1664 (2011)

관련 논문AI추천